Actively Recruiting
Evaluation of Amimestrocel Cell Therapy for Adults with Diabetic Kidney Disease Assessing Safety and Effectiveness with Scheduled Intravenous Infusions
Led by Chinese PLA General Hospital · Updated on 2026-07-14
120
Participants Needed
6
Research Sites
91 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of umbilical cord-derived mesenchymal stromal cells, called Amimestrocel, in adults with progressive diabetic kidney disease DKD. The study aims to find out if Amimestrocel can improve kidney function or reduce protein in the urine for patients with DKD. This is a phase 2 clinical trial sponsored by the Chinese PLA General Hospital. Participants receive Amimestrocel through intravenous infusions on a set schedule during the first month on days 1, 14, and 28, and then at weeks 8, 12, 16, 20, and 24. The dose starts at 1 million cells per kilogram in the first month and increases to 1.5 million cells per kilogram from week 8 through week 24. Participants continue with their standard treatment alongside the study intervention. During the trial, participants will be monitored closely with regular assessments of kidney function, urine protein levels, blood sugar control, and other health indicators up to 24 months after the first cell infusion. Researchers will track changes in urine protein, estimated glomerular filtration rate eGFR, blood glucose, HbA1c, and other markers related to kidney disease and overall health. Safety events will be recorded up to 28 weeks, and long-term effects will be observed for up to two years. Participants can expect multiple visits for infusions and follow-up assessments throughout the study period.
CONDITIONS
Brief Title
Safety and Efficacy of Mesenchymal Stromal Cells (Amimestrocel ) in Diabetic Kidney Disease
Research Team
X
xiangmei chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here